ImmunoMet Therapeutics Receives IND Clearance and Orphan Drug Designation from U.S. FDA for IM156 in Ideopathic Pulmonary Fibrosis and Completes Financing
Round Type
Funding Round
HoustonBiotechnologyHealth CareTherapeuticsDescription
ImmunoMet Therapeutics, Inc., a clinical stage biotechnology company targeting metabolism to develop novel anti-fibrotic and anti-cancer therapies, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for IM156, an investigational Protein Complex 1 inhibitor, being evaluated for idiopathic pulmonary fibrosis (IPF) as well as granting it Orphan Drug Designation. The Company also announced the closing of $7.0M in new financing by both existing and new investors that will be used, in part, to fund the Phase 1 program.
Quick answer
ImmunoMet Therapeutics raised an undisclosed amount in a Funding Round round, dated February 8, 2021. ImmunoMet Therapeutics is based in Houston, Texas, United States.
- How much did ImmunoMet Therapeutics raise?
- ImmunoMet Therapeutics raised an undisclosed amount in a Funding Round round on February 8, 2021.
- What does ImmunoMet Therapeutics do?
- ImmunoMet Therapeutics is a clinical stage biotech targeting cellular metabolism to develop novel anti-fibrotic and anti-tumor therapies.
- Where is ImmunoMet Therapeutics based and how big is it?
- ImmunoMet Therapeutics is based in Houston, Texas, United States. Fundz records about 7 employees.
- Who are the decision-makers at ImmunoMet Therapeutics?
- Fundz holds 1 contact at ImmunoMet Therapeutics, including the Board Director. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as ImmunoMet Therapeutics that raised within 45 days of this round, from Fundz verified event records.
- Camp4 Therapeutics Corp raised $15M on March 19, 2021.
- Boston Immune Technologies and Therapeutics (BITT) raised $10M (Series A) on March 17, 2021.
- Insitro raised $400M (Series C) on March 15, 2021.
- Century Therapeutics, Inc. raised an undisclosed amount on March 15, 2021.
- MapLight Therapeutics raised $30M on March 10, 2021.
- DTx Pharma, Inc. raised $100M on March 10, 2021.
Who to call at ImmunoMet Therapeutics, and when
A new round usually means ImmunoMet Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day ImmunoMet Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at ImmunoMet Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at ImmunoMet Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment ImmunoMet Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
ImmunoMet Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.